In vitro Anticancer and Insilico Studies of Quinoxaline‐sulfonyl‐1,2,4‐triazole Hybrids

Abstract

AbstractNew quinoxaline‐sulfonyl‐1,2,4‐triazole hybrids were synthesized (5 a–n) via systematic step‐wise sequence. Later, the in vitro cytotoxicity screening of all these compounds revealed that 2‐((4‐morpholino‐[1,2,4]triazolo[4,3‐a]quinoxalin‐1‐yl)sulfonyl)‐1‐(4‐nitrophenyl)ethenone (5 b), 1‐(4‐methoxy phenyl)‐2‐((4‐morpholino‐[1,2,4]triazolo[4,3‐a]quinoxalin‐1‐yl)sulfonyl) ethenone (5 d),4‐(2‐((4‐morpholino‐[1,2,4]triazolo[4,3‐a] quinoxaline‐1‐yl)sulfonyl)acetyl)benzonitrilen (5 g), 1‐(3,4‐dichloro phenyl)‐2‐((4‐morpholino[1,2,4]triazolo[4,3‐a]quinoxalin‐1‐yl) sulfonyl) ethenone (5 j) and 1‐(2,5‐dimethoxyphenyl)‐2‐((4‐morpholino[1,2,4]triazolo[4,3‐a]quinoxalin‐1‐yl)sulfonyl) ethenone (5 k) were found to more active against the four human cancer cell lines like Hep‐G2 (liver), A‐549 (lung), MCF‐7 (breast) and DU‐145 (prostate) with IC50 values ranging from 1.95±1.34 to 9.61 ±1.72 μM, whereas standard drug displayed IC50 values ranging from 1.97±0.45 to 3.08±0.13 μM. Predominately, compound 5 j displayed superior cytotoxicity against all cell lines than the standard etoposide. As well, the insilico studies of compounds 5 b, 5 d, 5 g, 5 j, and 5 k on EGFR receptor revealed that most potent compound 5 j strongly binds to protein EGFR (pdbid:4HJO). Finally, compounds 5 j and 5 g displayed superior inhibitory activity against tyrosine kinase EGFR than the standard erlotinib.